Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need new drugs either have their access long delayed, or denied.
While patients would undoubtedly like lower drug prices, they don’t want PMPRB actions to lead to developers deciding not to launch new medicines in Canada.
